Mepsevii
- Prescription status not stated
- Digestion, stomach, diabetes and nutrition
- Active substance
- Vestronidase alfa
- Made by
- Ultragenyx Germany GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Mepsevii is indicated for the treatment of non-neurological manifestations of Mucopolysaccharidosis VII (MPS VII; Sly syndrome).
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (MEPSEVII). It describes the substance, not this exact product.
Mucopolysaccharidosis VII (MPS VII or Sly syndrome) is a lysosomal disorder characterized by the deficiency of GUS that results in GAG accumulation in cells throughout the body leading to multisystem tissue and organ damage.
Vestronidase alfa-vjbk is a recombinant form of human GUS and is intended to provide exogenous GUS enzyme for uptake into cellular lysosomes.
Vestronidase alfa-vjbk is not expected to be eliminated through renal or fecal excretion.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-11-18
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Ultragenyx Germany GmbH |
|---|---|
| Active substance | Vestronidase alfa |
| Used in | Digestion, stomach, diabetes and nutrition |
| Classification | A16AB18 · Digestion, stomach, diabetes and nutrition |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2018-08-23 |
| Last updated by the regulator | 2026-07-08 |
| EMA product number | EMEA/H/C/004438 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).